Envisagenics, which is focused on discovering RNA therapeutics, has raised $2.25 million in seed funding. Dynamk Capital led the round.
Source: Press Release
Envisagenics, which is focused on discovering RNA therapeutics, has raised $2.25 million in seed funding. Dynamk Capital led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: